MOESM1 of Postoperative chemoradiotherapy is superior to postoperative chemotherapy alone in squamous cell lung cancer patients with limited N2 lymph node metastasis

Additional file 1. Associated Data.The file included the data of the treatment of 175 NSCLC patients. The treatment group was divided into 2 subgroups(0 for pCT and 1 for POCRT).The gender, age, ECOG scoring ,tumor position, Vessel invasion, T stage, Operation modality, Pathology, pN stage, Chemotherapy cycles, Total number of MLNs and CTV dose were divided into different subgroups according to the details list in the Table 1. The OS was calculated from the date of diagnosis to the date of death, or the date of the last follow-up. The survival group was divided into 2 subgroups (0 for survival and 1 for death). (XLSX 35 kb)

附件1：关联数据集
本数据集收录175例非小细胞肺癌（non-small cell lung cancer, NSCLC）患者的治疗相关临床数据。治疗组分为2个亚组：0对应pCT，1对应POCRT。性别、年龄、ECOG评分（Eastern Cooperative Oncology Group score）、肿瘤位置、血管侵犯、T分期、手术方式、病理分型、pN分期、化疗周期数、淋巴结总数（MLNs）及临床靶区（clinical target volume, CTV）剂量均按照表1中的详细细则进行亚组划分。总生存期（Overall Survival, OS）以患者确诊日期为起始时间，终止时间为死亡日期或末次随访日期。生存组分为2个亚组：0代表存活状态，1代表死亡状态。（文件格式：XLSX，大小：35 KB）